Introduction
============

Coronary artery bypass grafting (CABG) has been recognized as one of the most efficacious methods for treating coronary heart disease ([@b1-etm-0-0-2936]). Sevoflurane and propofol are commonly used anesthetics in CABG surgery ([@b2-etm-0-0-2936],[@b3-etm-0-0-2936]).

Propofol has a chemical structure that is similar to that of antioxidants, and has been shown to be able to scavenge free radicals *in vivo* ([@b4-etm-0-0-2936]). Previous studies have shown that propofol exerts different effects on various receptors and ion channels of the central nervous system ([@b5-etm-0-0-2936],[@b6-etm-0-0-2936]). Propofol is able to reduce β-adrenoreceptor-mediated signal transduction in cardiomyocytes, via a protein kinase C-dependent pathway. Furthermore, Sayin *et al* ([@b7-etm-0-0-2936]) proposed that propofol is able to attenuate myocardial lipid peroxidation during CAGB surgery. Corcoran *et al* ([@b8-etm-0-0-2936]) further suggested that propofol decreases free radical-mediated lipid peroxidation and the systemic inflammatory response in patients undergoing CAGB surgery.

Sevoflurane has been shown to serve a protective function in the pharmacological preconditioning of cardiac events in patients undergoing CABG ([@b9-etm-0-0-2936],[@b10-etm-0-0-2936]). Furthermore, sevoflurane reduces the incidence of late cardiac events during the first year following CABG surgery, which may occur by downregulating the expression of platelet endothelial cell adhesion molecule-1 ([@b9-etm-0-0-2936]). Yao *et al* ([@b11-etm-0-0-2936]) proposed that the myocardial protection exerted by sevoflurane in CABG surgery is achieved through the downregulation of troponin I. In addition, previous meta-analyses have further confirmed the protective effect of sevoflurane in cardiac surgery ([@b12-etm-0-0-2936],[@b13-etm-0-0-2936]).

Numerous studies have compared the myocardial protective effects of sevoflurane and propofol in patients undergoing CABG surgery, and the relative advantages and disadvantages of the two methods have been presented ([@b14-etm-0-0-2936],[@b15-etm-0-0-2936]). The use of sevoflurane appears to result in superior outcome compared with propofol in patients with little or no indication of ischemic heart disease, including patients undergoing CABG surgery ([@b16-etm-0-0-2936]). However, sevoflurane exhibits more marked antioxidative properties compared with propofol in patients undergoing off-pump CABG, as indicated by the results of a randomized controlled study ([@b17-etm-0-0-2936]). Furthermore, sevoflurane has been shown to possess stronger myocardial protective effects compared with propofol in patients undergoing CABG surgery ([@b18-etm-0-0-2936]). However, the underlying mechanisms of this protective effect remain unclear.

Microarray technology enables the global determination of gene expression levels, and is thus useful for the elucidation of underlying molecular mechanisms. Therefore, microarray analysis may useful for determining the effects of sevoflurane and propofol on gene expression in patients undergoing CABG. Lucchinetti *et al* ([@b19-etm-0-0-2936]) suggested that gene regulatory control of myocardial energy metabolism is closely associated with postoperative cardiac function. In the present study, a data set from the Gene Expression Omnibus (GEO) database (GSE4386; <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4386>) was downloaded and was subjected to screening for differentially expressed genes (DEGs). The aim of this study was to determine the influence of propofol and sevoflurane on postoperative recovery in patients following CABG. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to indicate the underlying molecular mechanisms of any effects and identify potential biomarkers. Such markers may facilitate the appropriate selection of sevoflurane or propofol, thereby improving the outcomes of patients undergoing CABG.

Materials and methods
=====================

### Gene expression data

The microarray data set GSE4386 was downloaded from the platform of GeneChip® Human Genome U133 Plus 2.0 Array of the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) ([@b20-etm-0-0-2936]). The data from a total of 40 samples was contained in the data set, including data from patients undergoing CABG surgery combined with sevoflurane treatment (n=10), propofol treatment (n=10) and control samples (n=20). The control samples comprised the same patients prior to CABG surgery. Atrial samples were collected prior to and following CABG surgery to determine gene expression profiles. The patients were treated in Triemli Hospital (Zurich, Switzerland). The mean ages of patients in the propofol and sevoflurane groups were 66.9 and 65.2 years, respectively. All patients were male. In addition, patients with hemodynamic instability was excluded. Microarray analysis was performed based on GSE4386, in which total RNA was prepared from the frozen cardiac tissue using an RNeasy Mini kit (Qiagen, Hilden, Germany).

### Pretreatment of raw data and DEGs analysis

Raw data were processed using Log2 transformation and quantile normalization, using SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA). The mRNA expression level was calculated based on the annotation files of probes. Gene expression profiles prior to and following anaesthesia with sevoflurane or propofol were compared using the R statistical program in a Limma software ([@b21-etm-0-0-2936]). The threshold of DEGs was considered to be P\<0.05 and log2 (fold-change) of \>1.

### Functional enrichment analysis

The database for Annotation, Visualization and Integration Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>) ([@b22-etm-0-0-2936]) provides analytical tools for analyzing a large list of genes, and was used to perform GO (<http://geneontology.org/page/go-enrichment-analysis>) and KEGG (<http://www.genome.jp/kegg/>) pathway enrichment analyses for DEGs. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Sevoflurane influences more genes compared with propofol at the transcriptional level

A total of 34,296 mRNA sequences (corresponding to 19,745 genes) were identified following raw data pretreatment. Compared with the control samples, 242 and 560 DEGs were detected in patients treated with propofol and sevoflurane, respectively ([Table I](#tI-etm-0-0-2936){ref-type="table"}). Following the comparison between the DEGs identified in the two treatment groups, 207 upregulated and 25 downregulated DEGs were found to overlap ([Fig. 1](#f1-etm-0-0-2936){ref-type="fig"}). By contrast, 116 upregulated and no downregulated DEGs were unique to sevoflurane, while 10 upregulated and 212 downregulated DEGs were unique to propofol.

### GO term and KEGG pathway enrichment analyses

Significantly enriched KEGG pathways and GO terms, and their enriched DEGs, are presented in [Table II](#tII-etm-0-0-2936){ref-type="table"}. A total of 10 KEGG pathways were enriched by 207 upregulated DEGs, while these DEGs enriched into 243 GO terms. As shown in [Fig. 2](#f2-etm-0-0-2936){ref-type="fig"}, the majority of the pathways of upregulated overlapping DEGs were associated with immune responses, such as Toll-like receptor (TLR), NOD-like receptor (NLR), Jak-STAT and MAPK signaling pathways, in addition to cytokine-cytokine receptor interaction. The KEGG enrichment results for downregulated DEGs associated with sevoflurane are presented in [Fig. 3](#f3-etm-0-0-2936){ref-type="fig"}. A total of three pathways were associated, including complement and coagulation cascades, glycolysis and drug metabolism. The pathway associated with cytokine-cytokine receptor interaction was found to be uniquely downregulated by sevoflurane.

As shown in [Fig. 4](#f4-etm-0-0-2936){ref-type="fig"}, the GO terms which were found to be significantly enriched in the 212 downregulated genes that were unique to sevoflurane could be divided into three groups: Immune response, glucose metabolism and response to vitamin and nutrient.

The GO biological pathways, which were found to be significantly over-represented in the 116 upregulated genes that were unique to sevoflurane could be divided into seven groups, including pathways associated with the immune response, apoptosis, cellular ion homeostasis and epithelial cell development. Among these pathways, those associated with cellular ion homeostasis ([Fig. 5A](#f5-etm-0-0-2936){ref-type="fig"}) and epithelial cell development ([Fig. 5B](#f5-etm-0-0-2936){ref-type="fig"}) were not detected among the pathways enriched by DEGs commonly upregulated by propofol and sevoflurane.

Discussion
==========

Sevoflurane and propofol are the two most commonly used anesthetics in CABG surgery ([@b23-etm-0-0-2936]). In the present study, a CABG patient data set (GSE4386) was downloaded from the GEO database to determine the molecular mechanisms underlying the effects of the two anesthetics. A total of 242 and 560 DEGs were identified in patients treated with propofol and sevoflurane, respectively. The two groups were found to have 207 downregulated DEGs in common, 116 that were unique to sevoflurane and 10 that were unique to propofol. In total, 25 downregulated genes were shared and 212 were unique to sevoflurane, while none was unique to propofol. The upregulated DEGs unique to sevoflurane were associated with cellular ion homeostasis and epithelial cell development, while the unique downregulated genes were associated with glucose metabolism, immune response and response to vitamin.

In the present study, pathways associated with cellular ion homeostasis, such as the regulation of membrane potential, cellular metal ion homeostasis and cellular calcium ion homeostasis, were enriched by upregulated DEGs unique to sevoflurane. Sevoflurane anesthesia has previously been shown to alter the electrophysiological activity of neurons by reducing hypoxic depolarization and enhancing the hypoxic hyperpolarization, thus protecting neurons against ischemia ([@b24-etm-0-0-2936]). Furthermore, sevoflurane has been found to increase coronary collateral blood flow through the activation of calcium-activated potassium channels ([@b25-etm-0-0-2936]). In the present study, the upregulated DEGs that were unique to sevoflurane were additionally associated with epithelial cell development, such as tissue morphogenesis, and epithelium and blood vessel development. Previously, sevoflurane treatment was shown to increase the synthesis of heat shock protein (HSP)-70 without affecting HSP-32 and HSP-27 synthesis ([@b26-etm-0-0-2936]). In the process of ischemia and reperfusion, HSP-70 was able to protect the heart through the expression of CD69 and by inducing a reduction in intracellular calcium ([@b27-etm-0-0-2936]). Sevoflurane may therefore serve a crucial function in mediating cardioprotection by influencing the pathways associated with cellular ion homeostasis and epithelial cell development.

In addition, unique downregulated DEGs associated with sevoflurane anesthesia were enriched in the pathways associated with glucose metabolism, immune response and response to vitamin in the present study. Saho *et al* ([@b28-etm-0-0-2936]) previously found that sevoflurane anesthesia may reversibly inhibit basal and glucose-stimulated insulin secretion, and further induce insulin resistance. Insulin resistance has been identified as an independent risk factor for coronary heart disease ([@b29-etm-0-0-2936]). Therefore, understanding the glycometabolic state of patients prior to CABG surgery is crucial in order to reduce the postoperative complications.

In the present study, these upregulated DEGs were enriched in pathways associated with the immune response, including innate, immunoglobulin-mediated and humoral immune responses; however, these upregulated pathways were additionally associated with the physical injury caused by CABG surgery, and thus were shared between sevoflurane and propofol. During the process of the immune response, TLRs have been confirmed as the signaling receptor for HSPs, mediating the synthesis of inflammatory cytokines ([@b30-etm-0-0-2936]). In addition, NLRs, TLRs and RIG-1-like receptors have been found to be involved in immune responses ([@b31-etm-0-0-2936]--[@b36-etm-0-0-2936]), and response to vitamin was shown to be a key pathway enriched by downregulated DEGs associated with sevoflurane anesthesia by the present results. Samadikhah *et al* ([@b37-etm-0-0-2936]) found that vitamin C combined with oral atorvastatin was significantly effective at preventing post-CABG atrial fibrillation. Furthermore, vitamin D, which is activated by a low-calcemic agonist, has been shown to modulate the humoral immune response, further affecting the efficacy of the surgical outcome of CABG ([@b38-etm-0-0-2936]). Collectively, these results suggest that sevoflurane exhibits a more marked effect on biological pathways compared with propofol, but exhibits a number of shortcomings. In order to achieve a more beneficial use of sevoflurane anesthesia in patients undergoing CABG, certain complementary therapies, such as the regulation of glucose balance and the use of vitamin supplements, should be considered.

In conclusion, the pathways enriched by DEGs, particularly those that were unique to sevoflurane and propofol, may affect surgical outcomes in patients undergoing CABG. In the present study, sevoflurane exhibited a more marked impact on the biological pathways investigated compared with propofol; however, the identified DEGs and pathways in this study were not investigated in animal models. Further study of this subject in animal models may be required in the future.
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###### 

Differentially expressed mRNA sequences and genes in propofol and sevoflurane.

  Parameter   P_up   P_down   S_up   S_down
  ----------- ------ -------- ------ --------
  mRNAs (n)   353    41       558    408
  Genes (n)   217    25       323    237

P, propofol; S, sevoflurane; P_up, upregulated genes in P; P_down, downregulated genes in P; S_up, upregulated genes in S; S_down, downregulated genes in S.

###### 

Numbers of significantly enriched KEGG pathways and GO terms.

  Parameter                   Up_common   P_up   S_up   P_up_uniq   S_up_uniq   down_common   P_down   S_down   P_done_uniq   S_done_uniq
  --------------------------- ----------- ------ ------ ----------- ----------- ------------- -------- -------- ------------- -------------
  Gene (n)                    207         217    323    10          116         25            25       237      0             212
  KEGG pathway (n)            10          10     13     1           1           0             0        3        0             4
  GO biological pathway (n)   243         250    321    4           95          0             0        49       0             50

P, propofol; S, sevoflurane; Up_common, upregulated genes common between P and S; P_up, upregulated genes in P; S_up, upregulated genes in S; P_up_uniq, upregulated genes unique to P; S_up_uniq, upregulated genes unique to S; Down_common, downregulated genes common between P and S; P_down, downregulated genes in P; S_down, downregulated genes in S; P_down_uniq, downregulated genes unique to P; S_down_uniq, downregulated genes unique to S. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
